This study is designed to monitor the safety of Boostagen® after it has been approved for use in Thailand. The study follows people who receive the vaccine in routine medical practice to identify and record any side effects. Doctors, nurses, and other healthcare professionals from hospitals and clinics in central, eastern, southern, and northern Thailand take part in the study. They report any health problems that occur after vaccination using standard reporting forms. The information collected helps researchers understand how safe the vaccine is when used in a large and diverse population under real-world conditions. Primary objective: To describe the post-licensure safety profile of Boostagen® in Thailand. Secondary objective: To identify any unexpected safety signals following vaccination with Boostagen®.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence and percentage of AEFIs following vaccination with Boostagen®
Timeframe: From the date of vaccination up to 30 days post-vaccination.
Incidence and percentage of pregnant women vaccinated with Boostagen® who had experienced complications during pregnancy
Timeframe: From administration of Boostagen® during pregnancy until delivery
Incidence and percentage of healthy and not healthy infants born to mothers who received Boostagen® during pregnancy
Timeframe: From maternal vaccination during pregnancy until birth of the infant